ANNX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANNX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Annexon has the Momentum Rank of 3.
For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.
Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.
For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
For the Biotechnology subindustry, Annexon's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Annexon's Momentum Rank distribution charts can be found below:
* The bar in red indicates where Annexon's Momentum Rank falls into.
Thank you for viewing the detailed overview of Annexon's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Ted Yednock | officer: EVP & Chief Innovation Officer | C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
Muneer A Satter | director | C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611 |
Jamie Dananberg | officer: Chief Medical Officer | 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Jennifer Lew | officer: EVP & Chief Financial Officer | 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710 |
Michael Overdorf | officer: EVP & Chief Business Officer | C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
Bain Capital Life Sciences Fund, L.p. | 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Douglas Love | director, officer: President & CEO | C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
Dean Richard Artis | officer: EVP & Chief Scientific Officer | C/O ANNEXON, INC., 1400 SIERRA PT PKWY, BLDG C, 2ND FLOOR, BRISBANE CA 94005 |
Bettina M. Cockroft | director | C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
Larry Mattheakis | officer: Chief Scientific Officer | C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
William D. Waddill | director | C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080 |
Sanjay Keswani | officer: EVP & Chief Medical Officer | C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
William H. Carson | director | C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK NY 10016 |
Clarus Lifesciences Iii, L.p. | 10 percent owner | 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
James E Flynn | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
From GuruFocus
By GlobeNewswire • 12-20-2023
By Marketwired • 09-19-2023
By sperokesalga sperokesalga • 02-16-2023
By Marketwired • 10-10-2023
By Stock market mentor Stock market mentor • 01-08-2023
By GlobeNewswire GlobeNewswire • 01-08-2023
By Marketwired • 08-07-2023
By Value_Insider Value_Insider • 11-03-2022
By sperokesalga sperokesalga • 02-27-2023
By GuruFocus Research • 11-15-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.